

KraneShares MSCI All China Health Care Index UCITS ETF

KraneShares MSCI All China Health Care Index UCITS ETF is a sub fund of KraneShares ICAV (the "ICAV"). The ICAV is authorised as a UCITS in Ireland and regulated by the Central Bank of Ireland.

Investors should read the Prospectus, Supplement and UK KIID and/or PRIIP KID prior to investing.

Investment Strategy:

KURE is an index-tracking, passively managed, UCITS ETF that is benchmarked to MSCI China All Shares Health Care 10/40 Index. The Index is a free float adjusted market capitalization weighted index designed to track the equity market performance of Chinese companies engaged in the health care sector. The securities in the Index include all types of publicly issued shares of Chinese issuers, which are listed in Mainland China, Hong Kong and the United States. Issuers eligible for inclusion must be classified under the Global Industry Classification Standard (GICS) as engaged in the healthcare sector. The issuers included in the Underlying Index may include small-cap, mid-cap and large-cap companies.

China Health Care Sector Highlights:

- China is the second largest healthcare market globally with total healthcare expenditures reaching \$1.06 trillion in 2021, increasing at an average annual growth rate of 12.78% over the last 5 years.¹
- There is still opportunity for considerable growth in China's healthcare market with per capita health spending at just \$813, compared to an average of over \$7,400 for the world's top eight healthcare markets².
- China's aging population, rising incomes and increasing urbanization may provide a sustained catalyst for growth in China's healthcare sector.

1. Data from Statista, last updated 30/Jun/2023.

2. China Briefing, "Understanding China's Rapidly Growing Healthcare Market", last updated 12/Jun/2023. Retrieved 30/Jun/2023.

Fund Details	Data as of 31/Jul/2023
Primary SEDOL	BMZ4LD0
Primary ISIN	IE00BL6K0S82
Inception Date	14/Jan/2021
Total Annual Fund Operating Expense	0.65%
Distribution Frequency	Accumulating
Index Name	MSCI China All Shares Health Care 10/40 Index
Net Assets	\$3,362,936
Number of Holdings	87
UK Reporting Fund Status	Reporting Fund
Investment Structure	UCITS
Base Currency	USD

Top 10 Holdings as of 31/Jul/2023 Holdings are subject to change.	Ticker	%
WUXI BIOLOGICS CAYMAN INC	2269	9.16
SHENZHEN MINDR-A	300760	6.53
JIANGSU HENGRU-A	600276	5.10
BEIGENE LTD	6160	4.71
AIER EYE HSPTL-A	300015	3.43
WUXI APPTec CO LTD-A	603259	3.32
CSPC PHARMACEUTI	1093	3.22
ZHANGZHOU PIEN-A	600436	3.14
INNOVENT BIOLOGICS INC	1801	2.11
CHONGQING ZHIF-A	300122	2.04

KURE Performance History:

	Cumulative % Data as of month end: 31/Jul/2023				Average Annualized % Data as of month end: 31/Jul/2023				Average Annualized % Data as of quarter end: 30/Jun/2023			
	1 Mo	3 Mo	6 Mo	Since Inception	1 Yr	3 Yr	5 Yr	Since Inception	1 Yr	3 Yr	5 Yr	Since Inception
Fund NAV	5.24%	-9.06%	-18.19%	-46.20%	-12.09%	-	-	-21.62%	-22.26%	-	-	-23.87%
Index	5.29%	-8.85%	-17.89%	-44.57%	-11.46%	-	-	-20.69%	-21.81%	-	-	-22.96%

The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investors shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted. For performance data current to the most recent month end, please visit www.kraneshares.eu.

Index returns are for illustrative purposes only. Index performance returns do not reflect any management fees, transaction costs or expenses. Indexes are unmanaged and one cannot invest directly in an index.

This is a marketing communication. Please refer to the prospectus of the UCITS, the KIID and the PRIIP before making any final investment decisions.

Listings as of 31/Jul/2023	Ticker	Currency	Listing Date	SEDOL	ISIN
London Stock Exchange	KURE LN	USD	14/Jan/2021	BMZ4LD0	IE00BL6K0S82
Borsa Italiana	KURE IM	EUR	13/Oct/2022	—	IE00BL6K0S82

Sector Breakdown	%
Data from Bloomberg as of 31/Jul/2023	
Health Care	100.00

Investing involves risk, including possible loss of principal. There can be no assurance that a Fund will achieve its stated objectives. The Funds are subject to political, social or economic instability within China which may cause decline in value. Fluctuations in currency of foreign countries may have an adverse effect to domestic currency values. Emerging markets involve heightened risk related to the same factors as well as increase volatility and lower trading volume.

This material is for information only and does not constitute an offer or recommendation to buy or sell any investment, or subscribe to any investment management or advisory service. It is not, under any circumstances, intended for distribution to the general public. You are accessing information which constitutes a financial promotion under section 21 of the Financial Services and Markets Act 2000 ("FSMA"). In relation to the United Kingdom, this information is only directed at, and may only be distributed to, persons who are "Investment Professionals" (being persons having professional experience in matters relating to investments) within the meaning of article 19(5) of the FSMA (Financial Promotion) Order 2005 (the "Financial Promotion Order"), persons to whom any of paragraphs (2)(a) to (d) of article 49 (high net worth companies, unincorporated associations etc.) of the financial promotion order apply, or persons to whom distribution may otherwise lawfully be made.

Any investment, and investment activity or controlled activity, to which this information relates is available only to such persons and will be engaged in only with such persons. Persons that do not have professional experience should not rely or act upon this information unless they are persons to whom any of paragraphs (2)(a) to (d) of article 49 apply to whom distribution of this information may otherwise lawfully be made.

The views and opinions expressed in this material are those of the authors Krane Fund Advisors. These opinions have been given in good faith, but are subject to change without notice. It is the responsibility of the investor to evaluate the accuracy, completeness and usefulness of any opinions, advice, services or other information provided.

In Switzerland, the Fund has appointed as Swiss Representative Waystone Fund Services (Switzerland) SA, Av. Villamont 17, 1005 Lausanne, Switzerland, Tel: +41 21 311 17 77, email: switzerland@waystone.com. The Fund's paying agent is Helvetische Bank AG. In respect of the Shares distributed in or from Switzerland, the place of performance and jurisdiction is Lausanne (Switzerland).

Krane Funds Advisors, LLC is appointed to act as investment manager in accordance with the requirements of the Central Bank. Waystone Management Company (IE) Limited is appointed to provide management services to the ICAV in accordance with the requirements of the Central Bank. The Management Company may decide to terminate the arrangements made for the marketing of the Fund in accordance with Article 93a of Directive 2009/65/EC.

For additional fund documentation, please visit www.waystone.com or www.kraneshares.eu. To view our Summary of Investor Rights, please visit www.kraneshares.eu or click here. [R-KS-EU]